Prognostic Implications of the Expression of CXCL16 in Breast Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Of the many prognostic factors for breast cancer, the relationship between an infiltration of inflammatory cells and the prognosis is debatable. Of the chemokines affecting cancer’s inflammatory reactions, chemokine (C-X-C motif) ligand 16 (CXCL16) has attracted attention for its prognostic value in many cancers, including colorectal cancer and renal cell carcinoma. But the situation for breast carcinoma is unknown. The aim of this study was to examine the relationship between the prognostic factors and the CXCL16 expression in patients with breast carcinoma. Methods: The patients (n=106) diagnosed with invasive ductal cancer of the breast were enrolled. We reviewed the clinicopathological factors of these patients, hematoxylin and eosin stains were prepared and estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2/neu) and CXCL16 immunostaining was performed. Results: The ER expression was significantly correlated with age and inflammation. A CXCL16 expression was noted in 81.1% of the cases. No association was evident between a CXCL16 expression and any other parameter, including the survival rate. Multivariate analysis did not implicate ER, HER2/neu or CXCL16 as an independent prognostic factor, but the tumor size was independent predictive factor for the patient outcome. Conclusions: An inflammatory reaction mediated by CXCL16 is not associated with the prognosis of breast cancer or any clinicopathological factors.
Abstract
Background: Of the many prognostic factors for breast cancer, the relationship between an infiltration of inflammatory cells and the prognosis is debatable. Of the chemokines affecting cancer’s inflammatory reactions, chemokine (C-X-C motif) ligand 16 (CXCL16) has attracted attention for its prognostic value in many cancers, including colorectal cancer and renal cell carcinoma. But the situation for breast carcinoma is unknown. The aim of this study was to examine the relationship between the prognostic factors and the CXCL16 expression in patients with breast carcinoma. Methods: The patients (n=106) diagnosed with invasive ductal cancer of the breast were enrolled. We reviewed the clinicopathological factors of these patients, hematoxylin and eosin stains were prepared and estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2/neu) and CXCL16 immunostaining was performed. Results: The ER expression was significantly correlated with age and inflammation. A CXCL16 expression was noted in 81.1% of the cases. No association was evident between a CXCL16 expression and any other parameter, including the survival rate. Multivariate analysis did not implicate ER, HER2/neu or CXCL16 as an independent prognostic factor, but the tumor size was independent predictive factor for the patient outcome. Conclusions: An inflammatory reaction mediated by CXCL16 is not associated with the prognosis of breast cancer or any clinicopathological factors.
참고문헌 (24)
- [URL]
- Ridolfi RL, "Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up", Cancer, 40, pp.1365~1385 (1977)
- Yoshimoto M, "Time dependency of the influence of prognostic factors on relapse in breast cancer", Cancer, 72, pp.2993~3001 (1993)
- Roses DF, "Pathologic predictors of recurrence in stage 1 (TINOMO) breast cancer", Am J Clin Pathol, 78, pp.817~820 (1982)
- Matloubian M, "A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo", Nat Immunol, 1, pp.298~304 (2000)
- Hojo S, "High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer", Cancer Res, 67, pp.4725~4731 (2007)
- Gutwein P, "Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients", Eur J Cancer, 45, pp.478~489 (2009)
- Darash-Yahana M, "The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation- associated cancers", PLoS One, 4, pp.e6695~ (2009)
- Jacobs TW, "Specificity of HercepTest in determining HER-2", neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, 1999, pp.17, 1983~1987
- Mori I, "Predictive and prognostic markers for invasive breast cancer", Pathol Int, 52, pp.186~194 (2002)
- Aamdal S, "Estrogen receptors and longterm prognosis in breast cancer", Cancer, 53, pp.2525~2529 (1984)
- Kinne DW, "Estrogen receptor protein in breast cancer as a predictor of recurrence", Cancer, 47, pp.2364~2367 (1981)
- Walker RA, "The aged breast", J Pathol, 211, pp.232~240 (2007)
- Muss HB, "c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer", N Engl J Med, 330, pp.1260~1266 (1994)
- Press MF, "HER-2", neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas, 1997, pp.15, 2894~2904
- Tsuda H, "Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases", Cancer, 65, pp.1794~1800 (1990)
- Rosen PP, "Immunohistochemical detection of HER2", neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis, 1995, pp.75, 1320~1326
- Feurino LW, "Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values", Cancer Invest, 24, pp.696~703 (2006)
- Erkan M, "Periostin creates a tumorsupportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity", Gastroenterology, 132, pp.1447~1464 (2007)
- Zlotnik A, "Chemokines and cancer", Int J Cancer, 119, pp.2026~2029 (2006)
- Abel S, "The transmembrane CXCchemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10", J Immunol, 172, pp.6362~6372 (2004)
- Shimaoka T, "Cell surface-anchored SR-PSOX", CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells, 2004, pp.75, 267~274
- Ludwig A, "Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells", J Neurochem, 93, pp.1293~1303 (2005)
- Fisher ER, "Types of tumor lymphoid response and sinus histiocytosis. Relationship to five-year, disease-free survival in patients with breast cancer", Arch Pathol Lab Med, 107, pp.222~227 (1983)